Rad Source Technologies Introduces Premier X-Ray Blood Irradiator RS 3400 at MEDLAB Middle East 2021
|
By LabMedica International staff writers Posted on 22 Jun 2021 |

Image: X-Ray Blood Irradiator RS 3400 (Photo courtesy of Rad Source Technologies)
Rad Source Technologies (Buford, GA, USA), a supplier of commercial X-ray radiation products designed to replace self-shielded gamma irradiators, highlighted its newly redesigned RS 3400 Blood Irradiator at MEDLAB Middle East 2021.
Blood transfusion is a lifesaving procedure for people who are bleeding and people who cannot make a sufficient amount of blood on their own. A rare but almost always fatal complication from blood transfusion is called transfusion-associated graft-versus-host disease (TA-GVHD), where immune cells from the donor blood attack the recipient’s organs and cause a deadly infection that is nearly impossible to fight off.
Over 20 years ago, Rad Source pioneered the first-ever FDA-approved blood X-ray irradiation medical device used to prevent TA-GVHD, and has maintained its status as the industry leader and gold-standard in blood irradiation technology and instrumentation ever since. The company’s patented X-ray irradiation technology effectively and routinely inactivates the immune cells in donor blood, which diminishes the risk of developing TA-GVHD for the transfusion recipient.
The RS 3400 is the first FDA cleared blood irradiation device with the highest product throughput and volume available. It processes a variety of blood configurations of up to 6L capacity in 5 minutes - whole blood bags, platelet bags and loaded syringes in the same cycle. Combination of the patented Quastar X-ray emitter, rotating carousel, and new canister with support inserts may achieve as low as 1.5 DUR. Radiation safety features of the RS 3400 include redundant safety interlocks to prevent intrusion in to the radiation chamber while in operation. The unit is a cabinet X-ray device that has external emissions far below the federal standard for such devices.
Related Links:
Rad Source Technologies
Blood transfusion is a lifesaving procedure for people who are bleeding and people who cannot make a sufficient amount of blood on their own. A rare but almost always fatal complication from blood transfusion is called transfusion-associated graft-versus-host disease (TA-GVHD), where immune cells from the donor blood attack the recipient’s organs and cause a deadly infection that is nearly impossible to fight off.
Over 20 years ago, Rad Source pioneered the first-ever FDA-approved blood X-ray irradiation medical device used to prevent TA-GVHD, and has maintained its status as the industry leader and gold-standard in blood irradiation technology and instrumentation ever since. The company’s patented X-ray irradiation technology effectively and routinely inactivates the immune cells in donor blood, which diminishes the risk of developing TA-GVHD for the transfusion recipient.
The RS 3400 is the first FDA cleared blood irradiation device with the highest product throughput and volume available. It processes a variety of blood configurations of up to 6L capacity in 5 minutes - whole blood bags, platelet bags and loaded syringes in the same cycle. Combination of the patented Quastar X-ray emitter, rotating carousel, and new canister with support inserts may achieve as low as 1.5 DUR. Radiation safety features of the RS 3400 include redundant safety interlocks to prevent intrusion in to the radiation chamber while in operation. The unit is a cabinet X-ray device that has external emissions far below the federal standard for such devices.
Related Links:
Rad Source Technologies
Latest MEDLAB 2021 News
- Ortho Exhibits VITROS Range of Diagnostic Testing and Automation Solutions at MEDLAB Middle East 2021
- MP Biomedicals Exhibits Diagnostics Kits and Sample Prep Solutions at MEDLAB Middle East 2021
- BD Demonstrates Latest Medtech Innovations at MEDLAB Middle East 2021
- Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021
- Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021
- Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021
- Nova Biomedical Showcases Advanced Point-of-Care Capillary Blood Analyzers at MEDLAB Middle East 2021
- Erba Mannheim Showcases Exciting New Introductions at MEDLAB Middle East 2021
- Bioperfectus Presents Advanced Infectious Disease Diagnostic Solutions at MEDLAB Middle East 2021
- PerkinElmer Demonstrates High-Throughput MSMS Dried Blood Spot Screening Solutions at Medlab Middle East 2021
- PerkinElmer’s EUROIMMUN Presents Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics
- LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event
- Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021
- MEDLAB Middle East 2021 Brings World of Laboratory Medicine Together Under ‘United by Business’ Show Theme
Channels
Clinical Chemistry
view channel
Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read moreMolecular Diagnostics
view channel
Cancer-Related Mutations in Immune Cells Linked to Alzheimer’s
Alzheimer’s disease is marked by protein aggregation and inflammatory changes in the brain’s immune system, yet its molecular drivers remain incompletely understood. With aging, human cells accumulate... Read more
Composite Blood Biomarkers Enable Early Detection of Common Cancers
Early diagnosis of colorectal, lung, and ovarian cancers remains challenging, with many patients identified only after tumors have begun to spread. A scalable blood test could expand access to screening,... Read more
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read moreHematology
view channel
Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Label-Free Microscopy Methodd Enables Faster, Quantitative Detection of Malaria
Microscopy of blood smears remains a cornerstone for malaria diagnosis but can be slow, stain-dependent, and operator intensive. With more than 200 million infections and over 600,000 deaths annually,... Read more
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
Pathologists are essential for cancer diagnosis and treatment planning, yet a global workforce shortage is straining services. Nearly 20 million new cases are diagnosed each year, and traditional artificial... Read more
AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
Prostate and breast cancers are among the most commonly diagnosed malignancies worldwide, and heterogeneous disease biology complicates risk stratification and treatment selection. Clinicians increasingly... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more








